BARDA seeks Amgen's Neupogen, Sanofi's Leukine for nuke attack countermeasures
This article was originally published in Scrip
Executive Summary
The US Biomedical Advanced Research and Development Authority (BARDA) has contracted with Amgen and Sanofi to purchase the firms' leukocyte growth factors (LGFs) to add to the Strategic National Stockpile – a cache of drugs, vaccines and other medical products intended for use in a large-scale emergency, such as a natural disaster or terrorist attack – for use as medical countermeasures (MCMs) in the event of a radiological or nuclear incident.